TABITHA
11 Nov 2020
Trial Summary
This study will collect data related to the management of women and men with HER2 positive metastatic breast cancer who are treated in routine clinical practice.
Acronym:
TABITHA
ACTRN/NCT /ethics:
ACTRN12615000232538
Scientific title:
Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2) Positive Australian Patient
Sponsor / Cooperative group:
BioGrid Australia Ltd
Trial & Patient Characteristics
| Cancer Type | Breast |
|---|---|
| Trial Type | Early detection, diagnosis, prognosis |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Breast |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Amanda Townsend |
| Recruitment Status | Not Yet Recruiting |